Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Herpes simplex virus tegument protein VP16 is a late structural protein found in the virion tegument layer of alphaherpesviruses such as HSV-1. VP16 plays a dual role, acting as a potent transcriptional activator of immediate-early viral genes by forming a complex with host proteins HCF-1 and Oct-1, thereby initiating the cascade required for lytic replication[3][5][6]. It is essential in viral assembly, functioning as a bridge between the inner and outer tegument and enabling proper virion maturation through interactions with viral capsid proteins and other tegument components[1][2][7]. The protein has a distinct, seat-like core structure and a disordered C-terminal activation domain that interfaces with host proteins and viral DNA elements[2][6]. VP16 is not considered a classical drug target, but is a critical factor for viral replication and pathogenesis in herpesvirus infections[5].
Not applicable (no approved or investigational drugs directly target this molecule as of current knowledge)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Herpes simplex virus tegument protein VP16 (VP16).